Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- FDA Approves Sensor-Embedded Abilify, World’s 1st Digital Pill
November 15, 2017
- Chugai to Offload 13 Off-Patent Brands to Taiyo Holdings
November 15, 2017
- Fujifilm Invests in Tsukuba-Based Upstart, Grabs Transgenic Technologies for iPS Cell Production
November 14, 2017
- Reported Off-Patent Drug Divestment “Not Based on Announcement”: Chugai
November 14, 2017
- Harvoni Drops Out of Top 10 Product List in Japan in June-September: IQVIA
November 13, 2017
- Ethical Drug Sales Up 0.7% in September; 1st DPP-4/SGLT2 Combo Upbeat: Crecon
November 10, 2017
- Takeda’s Relugolix Hits Primary Endpoint in Uterine Fibroids-Tied Pain: Japan PIII
November 10, 2017
- Ono Links Arms with Neurimmune on Neurodegenerative Disease
November 10, 2017
- Gilead’s VP for EMEA Hermans to Replace Orihara as Japan Head
November 10, 2017
- Can Japan’s 1st Enbrel Biosimilar Make Its Mark in RA Follow-On Arena with Self-Injection?
November 10, 2017
- Kyorin Pres. Says AG Strategy Is a “Success,” Nasonex Eyed as 2nd Battlefield
November 9, 2017
- Takata Seiyaku to Take Over MA for MSD’s Gentacin
November 9, 2017
- Mitsubishi Tanabe Grabs Distribution Rights to Clenafin/Jublia in Taiwan
November 9, 2017
- Top Court Dismisses Elplat Patent Infringement Case: Nichi-Iko
November 9, 2017
- Takeda Teams Up with US Medical Device Company to Develop Needle-Free Injection Device Utilizing Pressurized Liquid
November 9, 2017
- Evocalcet Shows Non-Inferiority to Regpara in Japan PIII
November 8, 2017
- Tolvaptan Re-Submitted to US FDA for ADPKD: Otsuka
November 8, 2017
- Santen Will Derive More than 30% of Sales Overseas This Fiscal Year: President
November 8, 2017
- Bayer to Put Digital Technology Proposals to Practical Use; AI-Based Automated Coding Will Reduce Workload by 40%
November 8, 2017
- Opdivo’s Half-Year Sales Sag as 50% Price Cut Takes Toll: Ono
November 7, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…